SQRX News

Squarex Pharmaceutical, a Phase 2 biotech developing a topical therapy for cold sores, withdrew its plans for an initial public offering on Friday. It originally filed in January 2023 with a proposed deal size of $15 million. Squarex's primary candidate, SQX770, was able to cut the number of cold sore outbreaks by 2.6-fold in the period from 42 to 120 days after a single topical...read more

Just one small IPO began trading this week as headline deal QuantaSing Group (QSG) delayed its offering; it now plans to price in the week ahead. The pipeline continued to see more activity, with six IPOs submitting initial filings, including three planning to raise $100 million. The week’s sole deal, Cadrenal Therapeutics (CVKD) raised...read more

Squarex Pharmaceutical, a Phase 2 biotech developing a topical therapy for cold sores, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. In its Phase 2 trial, the company's primary candidate, SQX770, was able to cut the number of cold sore outbreaks by 2.6-fold in the period from 42 to 120 days after a single topical dose on the arm, but failed...read more